药物之间的相互作用1329045个记录(本栏目收费,不能展示细节,电话13136136841)
药物之间的相互作用
Etidronic acid
Baricitinib
The risk or severity of adverse effects can be increased when Aldosterone is combined with Baricitinib.
Etidronic acid
Sirukumab
The risk or severity of adverse effects can be increased when Aldosterone is combined with Sirukumab.
Etidronic acid
Brodalumab
The risk or severity of adverse effects can be increased when Aldosterone is combined with Brodalumab.
Etidronic acid
Sarilumab
The risk or severity of adverse effects can be increased when Aldosterone is combined with Sarilumab.
Etidronic acid
Peficitinib
The risk or severity of adverse effects can be increased when Aldosterone is combined with Peficitinib.
Etidronic acid
Voclosporin
The risk or severity of adverse effects can be increased when Aldosterone is combined with Voclosporin.
Etidronic acid
Pirarubicin
The risk or severity of adverse effects can be increased when Aldosterone is combined with Pirarubicin.
Etidronic acid
Ravulizumab
The risk or severity of adverse effects can be increased when Aldosterone is combined with Ravulizumab.
Etidronic acid
Ixekizumab
The risk or severity of adverse effects can be increased when Aldosterone is combined with Ixekizumab.
Etidronic acid
Antilymphocyte immunoglobulin (horse)
The risk or severity of adverse effects can be increased when Aldosterone is combined with Antilymphocyte immunoglobulin (horse).
Etidronic acid
Peginterferon beta-1a
The risk or severity of adverse effects can be increased when Aldosterone is combined with Peginterferon beta-1a.
Etidronic acid
Vilanterol
The risk or severity of adverse effects can be increased when Aldosterone is combined with Vilanterol.
Etidronic acid
Dinutuximab
The risk or severity of adverse effects can be increased when Aldosterone is combined with Dinutuximab.
Etidronic acid
Olaparib
The risk or severity of adverse effects can be increased when Aldosterone is combined with Olaparib.
Etidronic acid
Palbociclib
The risk or severity of adverse effects can be increased when Aldosterone is combined with Palbociclib.
Etidronic acid
Blinatumomab
The risk or severity of adverse effects can be increased when Aldosterone is combined with Blinatumomab.
Etidronic acid
Vedolizumab
The risk or severity of adverse effects can be increased when Aldosterone is combined with Vedolizumab.
Etidronic acid
Obinutuzumab
The risk or severity of adverse effects can be increased when Aldosterone is combined with Obinutuzumab.
Etidronic acid
Pomalidomide
The risk or severity of adverse effects can be increased when Aldosterone is combined with Pomalidomide.
Etidronic acid
Dimethyl fumarate
The risk or severity of adverse effects can be increased when Aldosterone is combined with Dimethyl fumarate.